Form 4: CRISPR CEO Kulkarni Reports Equity Transactions

CRISPR Therapeutics CEO Samarth Kulkarni reported the acquisition of common shares from RSU vesting, a tax-related sale, and new grants of stock options and restricted stock units.

Summary

• Samarth Kulkarni, CEO and Director of CRISPR Therapeutics AG, acquired 19,687 common shares on March 20, 2026, through the vesting of restricted stock units.
• Kulkarni subsequently sold 10,020 common shares at $46.78 per share on March 23, 2026, to cover tax withholding obligations related to the RSU vesting. This was a mandated sale, not a discretionary trade.
• A new stock option grant for 114,249 common shares was issued on March 20, 2026, with an exercise price of $46.24 and a 10-year expiration. These options will vest in 48 equal monthly installments starting April 20, 2026.
• A new restricted stock unit award for 81,875 common shares was granted on March 20, 2026, vesting in four equal annual installments starting March 20, 2027.
• Following these transactions, Kulkarni directly beneficially owns 255,501 common shares, 114,249 stock options, and 81,875 restricted stock units (from the new grant) plus 39,375 restricted stock units (remaining from a 2024 grant).
• Some shares remain subject to a lock-up agreement related to the Issuer's convertible senior notes offering due 2031.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. While there was a tax-related sale, the significant grants of new stock options and restricted stock units to the CEO align management's interests with long-term shareholder value, indicating confidence in future performance.

Positives

• CEO Samarth Kulkarni received a significant grant of 114,249 stock options with a 10-year term, aligning his long-term incentives with shareholder value.
• A new restricted stock unit award of 81,875 shares was granted, further tying executive compensation to future company performance.
• The vesting of 19,687 restricted stock units indicates the achievement of prior performance or time-based milestones.

Negatives

• The sale of 10,020 common shares, although for tax withholding, reduces the CEO's direct common share ownership by that amount.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those related to compensation grants and tax-mandated sales, are common in the biotechnology sector as a form of executive incentive and compensation management. These transactions typically reflect pre-established compensation plans rather than discretionary market timing.

Stakeholder Impact

• Shareholders: The grants of equity awards to the CEO align management's incentives with shareholder interests, potentially fostering long-term value creation. The tax-related sale is a routine event and not indicative of a lack of confidence.
• Employees: The compensation structure for the CEO may reflect broader compensation strategies within the company.

Next Steps

• Vesting of 114,249 stock options in 48 equal monthly installments, starting April 20, 2026.
• Vesting of 81,875 restricted stock units in four equal annual installments, starting March 20, 2027.
• Further vesting of the 2024 RSU award on March 20, 2027, and March 20, 2028.

Key Dates

Recommendation

The filing details routine insider transactions, primarily related to executive compensation grants and a tax-mandated sale, executed under a pre-planned Rule 10b5-1 agreement. These actions do not signal a significant change in the company's fundamental outlook or the CEO's discretionary view on the stock, thus warranting a 'hold' recommendation for seasoned investors.

Keywords

CRISPR Therapeutics, CRSP, Samarth Kulkarni, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Executive Compensation, Biotechnology, Gene Editing